Related Experiment Video
Updated: May 5, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review
Mohit Kumar1, Anjali Pant2, Syed Mahmood3,4,5
1Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University (MRSPTU), Bathinda, 151001, Punjab, India.
Introduction:
Osteoporosis (OP) is a prevalent condition in postmenopausal women, marked by reduced bone density and an increased risk of fractures. Raloxifene (RLX), a selective estrogen receptor modulator (SERM), is the only drug approved for the management of OP in this patient population. RLX works by mimicking estrogen's effects on bone, reducing bone resorption and thereby increasing bone mineral density. However, despite its benefits, conventional oral RLX formulations have significant limitations. Its low bioavailability and poor aqueous solubility are compounded by extensive first-pass metabolism, which significantly reduces the drug's efficacy. Recent research has focused on nanocarriers for RLX to overcome these challenges, with lipid-based nanocarriers emerging as a promising approach to improve solubility, enhance absorption, and bypass first-pass metabolism via lymphatic uptake.
Methods:
The authors gathered information about RLX from articles published up to 2025 and listed in Pub- Med, Web of Science, Elsevier, Google Scholar, and similar databases. The keywords used in our search included "Osteoporosis" "Raloxifene" "nanocarriers" etc. Results: The review of existing literature reveals substantial progress in developing innovative drug delivery systems for RLX, aimed at overcoming the limitations of conventional oral dosage forms in the treatment of OP and cancer. Several studies underscore the potential of novel formulations, including lipid-based nanocarriers, to improve raloxifene's pharmacokinetic profile, particularly through enhanced solubility, dissolution rate, and bioavailability.
Conclusion:
The nanocarriers mediated raloxifene delivery represent promising strategies to enhance its bioavailability and therapeutic efficacy in osteoporosis treatment. By improving solubility and bypassing first-pass metabolism, these novel systems can potentially reduce dose-related side effects, offering safer and more effective long-term options for postmenopausal women with osteoporosis. This approach supports the continued exploration of both oral and non-oral delivery methods to overcome the limitations of conventional raloxifene formulations.
Insights
Nanocarriers enhance raloxifene delivery for osteoporosis, improving bioavailability and reducing side effects. This approach offers a safer, more effective treatment for postmenopausal women with osteoporosis.
Area of Science:
- Pharmacology and Drug Delivery
- Biomedical Engineering
- Materials Science
Background:
- Osteoporosis (OP) is a significant health concern for postmenopausal women, increasing fracture risk.
- Raloxifene (RLX), a selective estrogen receptor modulator (SERM), is a key treatment for OP, but conventional oral forms have low bioavailability and efficacy due to poor solubility and first-pass metabolism.
- Nanocarrier systems, particularly lipid-based ones, are being explored to enhance RLX solubility, absorption, and bypass first-pass metabolism via lymphatic uptake.
Purpose of the Study:
- To review the progress in developing nanocarrier-based drug delivery systems for Raloxifene (RLX).
- To evaluate the potential of these novel formulations in overcoming the limitations of conventional oral RLX for osteoporosis (OP) treatment.
- To highlight the benefits of nanocarrier-mediated delivery for improving RLX's pharmacokinetic profile and therapeutic efficacy.
Main Methods:
- A comprehensive literature search was conducted using databases like PubMed, Web of Science, Elsevier, and Google Scholar.
- Keywords included "Osteoporosis," "Raloxifene," and "nanocarriers" to identify relevant studies published up to 2025.
- Existing research on novel RLX formulations and their impact on pharmacokinetic properties was reviewed.
Main Results:
- Substantial progress has been made in developing innovative nanocarrier-based drug delivery systems for RLX.
- Lipid-based nanocarriers show significant potential for improving RLX's solubility, dissolution rate, and bioavailability.
- These novel formulations aim to overcome the limitations of conventional oral dosage forms in treating OP and cancer.
Conclusions:
- Nanocarrier-mediated RLX delivery presents a promising strategy to enhance bioavailability and therapeutic efficacy for osteoporosis.
- Improved solubility and bypassing first-pass metabolism can lead to reduced dose-related side effects, offering safer long-term treatment options.
- Further exploration of both oral and non-oral nanocarrier delivery methods is supported to optimize RLX therapy for postmenopausal women.
